Abstract 522P
Background
The standard treatment of relapsed small cell lung cancer (SCLC) has not been established yet, and weekly paclitaxel (PTX) is recommend as one of the treatment options for relapsed SCLC. In advanced non-small cell lung cancer, nanoparticle albumin-bound paclitaxel (nab-PTX) has shown equal activity to PTX with less neurological adverse event. However, the benefit of nab-PTX for relapsed SCLC has not been fully evaluated yet. The aim of this study is to evaluate efficacy and safety of both weekly nab-PTX and weekly PTX regimen for relapsed SCLC.
Methods
We retrospectively reviewed consecutive relapsed SCLC patients who were treated with weekly nab-PTX (80mg/m2, day1,8,15/q4 weeks) or weekly PTX (80mg/m2, day1,8,15,22/q4 weeks) at Tosei general hospital, from January 2008 to March 2019. We evaluated the objective response rate (ORR), disease control rate (DCR), progression free survival (PFS), overall survival (OS) and adverse event profile in each regimen.
Results
A total of 52 patients with relapsed SCLC were reviewed, 18 and 34 patients received weekly nab-PTX (group A) and weekly PTX (group B), respectively. Patient characteristics (group A: group B) were as follows; male 17 (94%): 28(82%), median of age 74 :70, ECOG-PS 0-1 18(100%) :29(85%), extensive disease 14(78%) :17(50%), refractory relapse 16(89%) :20(59%). ORR in group A and B were 5.6% and 8.8%, and DCR in group A and B were 55.6% and 38%, respectively. The PFS and OS had no difference between group A and B (median PFS, 3.2months and 1.7months; median OS, 5.4 months and 4.5months). Toxicity profile of group A was tolerable as well as group B. About neurological adverse event, group A had less toxicity than group B in any grade (5(28%) and 12(35%) patients) but no severe adverse event was observed.
Conclusions
Weekly nab-PTX and weekly PTX showed similar efficacy for relapsed SCLC. In terms of toxicity, weekly nab-PTX might be less toxic especially in neurological adverse event. Although this is a retrospective single center study, the nab-PTX might be a treatment option for relapsed SCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hajime Oi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract